Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online July 16, 2007
Diabetes 56:2579-2588, 2007
DOI: 10.2337/db06-1207
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db06-1207v1
56/10/2579    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kwan, E. P.
Right arrow Articles by Gaisano, H. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwan, E. P.
Right arrow Articles by Gaisano, H. Y.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Interaction Between Munc13-1 and RIM Is Critical for Glucagon-Like Peptide-1–Mediated Rescue of Exocytotic Defects in Munc13-1–Deficient Pancreatic ß-Cells

Edwin P. Kwan1, Li Xie1, Laura Sheu1, Toshihisa Ohtsuka2, and Herbert Y. Gaisano1

1 Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada
2 Department of Clinical and Molecular Pathology, University of Toyama, Toyama, Japan

Address correspondence and reprint requests to Dr. Herbert Y. Gaisano, Medical Sciences Bldg., Rm. 7226, 1 King's College Circle, University of Toronto, Toronto, Ontario M5S 1A8, Canada. E-mail: herbert.gaisano{at}utoronto.ca

Abbreviations: 8-pCPT-2'-O-Me-cAMP, 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate; AUC, area under the curve; BBDC, Banting and Best Diabetes Center; CIHR, Canadian Institutes of Health Research; Cm, membrane capacitance; DAG, diacylglycerol; Epac, exchange protein directly activated by cAMP; F-PIS, first-phase insulin secretion; GLP-1, glucagon-like peptide-1; GSIS, glucose-stimulated insulin secretion; GST, glutathione S-transferase; IBMX, isobutylmethylxanthine; KATP channel, ATP-sensitive K+ channel; KRBH, Krebs-Ringer bicarbonate HEPES buffer; N6-Bnz-cAMP, N6-benzoyladenosine-cAMP; PKA, protein kinase A; RIA, radioimmunoassay; Rim, Rab3A-interacting molecule; RRP, readily releasable pool; SNAP, soluble N-ethylmaleimide–sensitive factor attachment protein; SNARE, SNAP receptor; S-PIS, second-phase insulin secretion; SUR1, sulfonylurea receptor 1

OBJECTIVE—Glucagon-like peptide-1 (GLP-1) rescues insulin secretory deficiency in type 2 diabetes partly via cAMP actions on exchange protein directly activated by cAMP (Epac2) and protein kinase A (PKA)-activated Rab3A-interacting molecule 2 (Rim2). We had reported that haplodeficient Munc13-1+/– mouse islet ß-cells exhibited reduced insulin secretion, causing glucose intolerance. Munc13-1 binds Epac2 and Rim2, but their functional interactions remain unclear.

RESEARCH DESIGN AND METHODS—We used Munc13-1+/– islet ß-cells to examine the functional interactions between Munc13-1 and Epac2 and PKA. GLP-1 stimulation of Munc13-1+/– islets normalized the reduced biphasic insulin secretion by its actions on intact islet cAMP production and normal Epac2 and Rim2 levels.

RESULTS—To determine which exocytotic steps caused by Munc13-1 deficiency are rescued by Epac2 and PKA, we used patch-clamp capacitance measurements, showing that 1) cAMP restored the reduced readily releasable pool (RRP) and partially restored refilling of a releasable pool of vesicles in Munc13-1+/– ß-cells, 2) Epac-selective agonist [8-(4-chloro-phenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate] partially restored the reduced RRP and refilling of a releasable pool of vesicles, and 3) PKA blockade by H89 (leaving Epac intact) impaired cAMP ability to restore the RRP and refilling of a releasable pool of vesicles. Conversely, PKA-selective agonist (N6-benzoyladenosine-cAMP) completely restored RRP and partially restored refilling of a releasable pool of vesicles. To determine specific contributions within Epac-Rim2–Munc13-1 interaction sites accounting for cAMP rescue of exocytosis caused by Munc13-1 deficiency, we found that blockade of Rim2–Munc13-1 interaction with Rim-Munc13-1–binding domain peptide abolished cAMP rescue, whereas blockade of Epac-Rim2 interaction with Rim2-PDZ peptide only moderately reduced refilling with little effect on RRP.

CONCLUSIONS—cAMP rescue of priming defects caused by Munc13-1 deficiency via Epac and PKA signaling pathways requires downstream Munc13-1–Rim2 interaction.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.